JP2022533318A - 気道感染の治療または予防のためのサブユニットワクチン - Google Patents

気道感染の治療または予防のためのサブユニットワクチン Download PDF

Info

Publication number
JP2022533318A
JP2022533318A JP2021564088A JP2021564088A JP2022533318A JP 2022533318 A JP2022533318 A JP 2022533318A JP 2021564088 A JP2021564088 A JP 2021564088A JP 2021564088 A JP2021564088 A JP 2021564088A JP 2022533318 A JP2022533318 A JP 2022533318A
Authority
JP
Japan
Prior art keywords
protein
seq
sequence
hmpv
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533318A5 (https=
Inventor
ペルギ，ファビエン
シュワンボルン，クラウス
シュラー，ウォルフガング
ルンドベルグ，アーバン
マインケ，アンドレアス
Original Assignee
ヴァルネヴァ エスイー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァルネヴァ エスイー filed Critical ヴァルネヴァ エスイー
Publication of JP2022533318A publication Critical patent/JP2022533318A/ja
Publication of JP2022533318A5 publication Critical patent/JP2022533318A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021564088A 2019-05-20 2020-05-19 気道感染の治療または予防のためのサブユニットワクチン Pending JP2022533318A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
EP19175413.4 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (2)

Publication Number Publication Date
JP2022533318A true JP2022533318A (ja) 2022-07-22
JP2022533318A5 JP2022533318A5 (https=) 2023-05-31

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564088A Pending JP2022533318A (ja) 2019-05-20 2020-05-19 気道感染の治療または予防のためのサブユニットワクチン

Country Status (21)

Country Link
US (3) US12162907B2 (https=)
EP (1) EP3972639A1 (https=)
JP (1) JP2022533318A (https=)
KR (1) KR20220010478A (https=)
CN (1) CN114127101A (https=)
AU (1) AU2020277661A1 (https=)
BR (1) BR112021021637A2 (https=)
CA (1) CA3138064A1 (https=)
CL (1) CL2021002819A1 (https=)
CO (1) CO2021014694A2 (https=)
EC (1) ECSP21079178A (https=)
GB (1) GB2598494B (https=)
IL (1) IL287099A (https=)
MX (1) MX2021013111A (https=)
MY (1) MY208001A (https=)
PE (1) PE20220400A1 (https=)
PH (1) PH12021552736A1 (https=)
SA (1) SA521430813B1 (https=)
SG (1) SG11202110646PA (https=)
WO (1) WO2020234300A1 (https=)
ZA (1) ZA202106883B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
KR102860080B1 (ko) 2020-10-09 2025-09-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 융합전-안정화된 hmpv f 단백질
AU2021380755A1 (en) 2020-11-13 2023-06-22 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
US20240335523A1 (en) * 2021-08-05 2024-10-10 The Regents Of The University Of California Glycoengineered Foldon Domains and Related Compositions and Methods
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体：制造方法和用途
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN119176858B (zh) * 2024-11-22 2026-01-09 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097089A2 (de) * 2002-05-16 2003-11-27 Lohmann Animal Health Gmbh & Co. Kg Attenuierung von metapneumovirus
JP2016522230A (ja) * 2013-06-17 2016-07-28 クルセル ホランド ベー ヴェー 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
US20180008697A1 (en) * 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use
US20190030156A1 (en) * 2015-08-31 2019-01-31 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
AU2002358616A1 (en) 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097089A2 (de) * 2002-05-16 2003-11-27 Lohmann Animal Health Gmbh & Co. Kg Attenuierung von metapneumovirus
JP2016522230A (ja) * 2013-06-17 2016-07-28 クルセル ホランド ベー ヴェー 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
US20180008697A1 (en) * 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use
US20190030156A1 (en) * 2015-08-31 2019-01-31 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections

Also Published As

Publication number Publication date
WO2020234300A1 (en) 2020-11-26
PH12021552736A1 (en) 2022-07-11
MX2021013111A (es) 2021-11-17
MY208001A (en) 2025-04-03
CO2021014694A2 (es) 2022-01-17
US12162909B2 (en) 2024-12-10
SG11202110646PA (en) 2021-10-28
IL287099A (en) 2021-12-01
GB2598494B (en) 2024-07-24
KR20220010478A (ko) 2022-01-25
SA521430813B1 (ar) 2024-04-27
ECSP21079178A (es) 2021-11-30
BR112021021637A2 (pt) 2021-12-21
GB202114836D0 (en) 2021-12-01
CN114127101A (zh) 2022-03-01
ZA202106883B (en) 2022-07-27
EP3972639A1 (en) 2022-03-30
US20250171501A1 (en) 2025-05-29
CL2021002819A1 (es) 2022-07-08
AU2020277661A1 (en) 2021-10-21
PE20220400A1 (es) 2022-03-22
US20220185847A1 (en) 2022-06-16
GB2598494A (en) 2022-03-02
US20240067681A1 (en) 2024-02-29
US12162907B2 (en) 2024-12-10
CA3138064A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US12162909B2 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
KR102638978B1 (ko) Rsv에 대한 백신
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
USRE47471E1 (en) Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
US20240181034A1 (en) Human metapneumo virus vaccine
US20180008697A1 (en) Recombinant metapneumovirus f proteins and their use
KR20160002938A (ko) 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
JP2016525889A (ja) インフルエンザウイルスワクチンおよびその使用
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
CN117202928A (zh) 用于偏肺病毒的基于蛋白质的纳米颗粒疫苗
KR20190012193A (ko) 안정화된 융합-전 rsv f 단백질
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
CN119161495B (zh) 呼吸道合胞病毒重构多肽及其应用
HK40098178A (zh) 人偏肺病毒疫苗
JP2020162607A (ja) インフルエンザウイルスワクチンおよびその使用
NZ752808B2 (en) Stabilized soluble prefusion rsv f polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241120